hyperlipemia in equids
DESCRIPTION
Presentation for VMC 979 (Equine Medicine, senior clinical rotation) discussing basic details of hyperlipemia in equids. Includes signalment, risk factors, pathogenesis, clinical signs, diagnosis, treatment, and prognosis.TRANSCRIPT
Omega CantrellVMC 979
HYPERLIPEMIA IN EQUIDS
Clinical manifestation of a severe imbalance between energy intake and demand Similar to ketosis in dairy cattle, but with triglycerides
(TGs) rather than ketones as a consequence of this negative energy balance
Definitions Hyperlipidemia
Serum [TG] increased but <500ng/dL Hyperlipemia
Serum [TG] >500ng/dL
THE BASICS
Breed predilection Ponies, pony crosses, mini horses, donkeys, mini donkeys
Body condition Obese animals (greater fat stores)
Risk factors Obesity, lactation/pregnancy, stress/transportation Concurrent disease/state of increased demand with
decreased intake (especially in high risk breeds) Chronic internal parasitism, colitis, colic, poor nutrition, etc. Anything that would cause an animal to go off-feed, thus
resulting in decreased energy intake compared to increased metabolic demands
SIGNALMENT, HISTORY, RISK FACTORS
Negative energy balance = fatty acids (FAs) mobilized from adipose tissue Most animals = production of ketones from FAs Equids ≠ ketones large amounts of mobilized lipids in
circulation Problem is TG overproduction, not catabolic failure
Hyperlipemic ponies = lipoprotein lipase (LPL) activity is 2x that of healthy animals of the same breed
May be precipitated by insulin resistance Insulin inhibits hormone sensitive lipase (HSL, responsible for
mobilization of fatty acids from adipose tissue) Resistance = increased HSL activity = more FA mobilization,
increased TGs Exacerbated by risk factors (obesity, pregnancy, stress)
High serum [TG] may prolong/complicate recovery
PATHOPHYSIOLOGY
Often referable to the primary disease Hyperlipemia is typically a secondary problem
Can see severe depression, anorexiaNon-specific signs measure serum [TG] in
depressed, inappetant animals of at-risk breeds
CLINICAL SIGNS
Serum [TG] May also diagnose with PCV/TS – will see cloudy/white
(lipemic) serum once hemocrit tube is centrifugedHepatic/renal function, chemistry profi le
Assessing for an underlying cause; can also help prognostically
Any diagnostics need for evaluation of the primary condition YOU MUST TREAT THE UNDERLYING DISEASE!
DIAGNOSIS
Hepatic failureRenal failureDeath
If it can be identified, YOU MUST TREAT THE PRIMARY DISEASE! = often ends up being an expensive treatment, due to
need for diagnostics and aggressive treatment in most cases
COMPLICATIONS
Nutritional support Reverses negative energy balance, increases serum [GLUC],
promotes endogenous insulin release, inhibits lipid mobilization from peripheral stores
“Smorgasbord” approach, enteral, parenteral (rarely)Resolve the primary disease! Insulin therapy
May not be effective if insulin resistance is presentHeparin therapy
Enhances lipogenesis via stimulation of LPL, but no longer recommended (LPL high in affected individuals)
Contraindicated if coagulopathic due to liver dysfunction No longer recommended as a mainstay of therapy
TREATMENT
Poor to grave Mortality 43-80%
Survival in mini horses and donkeys (78%) vs. ponies (20-57%)
Prognosis worsens if renal involvement is present Development or worsening of azotemia Renal failure can cause further anorexia, which will
exacerbate hyperlipemia; also results in build up of toxins in the body
Death is more often from failure to treat the primary disease
These animals are typically presented when signs are advanced, thus rapid, aggressive treatment is often required Can become very expensive very quickly combination of
poor prognosis with a large estimate for care often results in euthanasia
PROGNOSIS
Boyce, M. (1999). Hyperlipemia in Ponies and Miniature Horses. Available: http://wwwchem.csustan.edu/chem4400/sjbr/99boyce.htm. Last accessed 24 October 2013.
Semrad, SD. (2012). Hyperlipemia and Hepatic Lipidosis in Large Animals. In: Aiello, SE et al. The Merck Veterinary Manual. Whitehouse Station, NJ: Merck Sharp & Dome Corp.
Watson, T et al. (2013). Hyperlipemia Syndrome. Available: http://www.vetstream.com/equis/Content/Disease/dis00329. Last accessed 24 October 2013.
REFERENCES